Indication
Ovarian Mucinous Cystadenocarcinoma
5 clinical trials
3 products
8 drugs
Clinical trial
A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2020-12-31
Product
BevacizumabProduct
SapanisertibClinical trial
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)Status: Active (not recruiting), Estimated PCD: 2024-06-30
Drug
AtezolizumabDrug
AbraxaneClinical trial
A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2021-07-27
Clinical trial
A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)Status: Active (not recruiting), Estimated PCD: 2015-02-25
Drug
UTD1Drug
AN0025Drug
mFOLFOX6Drug
TiragolumabClinical trial
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersStatus: Active (not recruiting), Estimated PCD: 2022-02-03
Drug
AdavosertibDrug
Gemcitabine